Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections
Ruwen Böhm, Claudia Bulin, Vicki Waetzig, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 11, pp. 4421-4431
Open Access | Times Cited: 67

Showing 26-50 of 67 citing articles:

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
Yifei Xue, Shuo Feng, Guangyao Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
Cuicui Sun, Xiaoyan Yang, Linlin Tang, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 8, pp. 1049-1060
Closed Access | Times Cited: 7
Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence
Zeying Feng, Qiuping Zhao, Jingjing Wu, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 7
A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
L X Tang, Cuicui Sun, Wen‐Shan Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database
Weihong Chen, Shaobin Li, Dongqin Huang, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 3
Open Access | Times Cited: 2
Salbutamol, a Short Acting Beta-2 Agonist, Reduces Risk and Improves Prognosis of Prostate Cancer
Steven Lehrer, Peter H. Rheinstein
American Journal of Clinical Oncology (2024) Vol. 47, Iss. 12, pp. 591-594
Open Access | Times Cited: 2
Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports
Pengjiao An, Xin Liu, Bo Zhang
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 119-128
Closed Access | Times Cited: 6
Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database
Jing Zhang, Ting Qiu, Yiting Zhou, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 9, pp. 849-856
Closed Access | Times Cited: 5
Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database
Harsha Prakash Nair, Apoorva Rachana Kulkarni, Maheswari Eswaran, et al.
Arab Journal of Gastroenterology (2023) Vol. 24, Iss. 1, pp. 1-4
Open Access | Times Cited: 4
Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real‐World Pharmacovigilance and Randomized Clinical Trials
Han Qu, Jiaqi Wu, Cui Ma, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 1, pp. 201-210
Closed Access | Times Cited: 4
Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis
Xuyan Wang, Donghong Yin, Yang Tang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
Rui Xiong, Lei Jing, Sicen Pan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
Yibei Zhao, Huiming Jiang, Lifen Xue, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 2, pp. 480-487
Closed Access | Times Cited: 1
Safety Profile of Paxlovid in the Treatment of COVID-19
Bing Lv, Xin Gao, Guoqiang Zeng, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 9, pp. 666-675
Closed Access | Times Cited: 1
Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
Xiaomei Xiong, Xiuwen Zhang, Xiaoxia Li, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 11, pp. 1447-1452
Closed Access | Times Cited: 1
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
Yi Zhao, Yuzhou Zhang, Lin Yang, et al.
Annals of Pharmacotherapy (2024) Vol. 58, Iss. 11, pp. 1105-1116
Closed Access | Times Cited: 1
Antiviral influenza treatments and hemorrhage‐related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database
Jyotirmoy Sarker, Emir Carkovic, Karolina Ptaszek, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 5, pp. 383-393
Open Access | Times Cited: 1
Bisphosphonates and Cardiac Arrhythmia: An Analysis of the FDA Adverse Event Reporting System (FAERS)
Feifei Wang, Qian Wang, Chengting Rong, et al.
(2024)
Closed Access | Times Cited: 1
Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database
Manxue Jiang, Hao Li, Lingti Kong
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS
Han Qu, Wenjing Li, Zhenhua Wu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports
Zhihui Zhang, Xin Liu, Jinlan Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-7
Closed Access | Times Cited: 1
A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy
Owais M. Aftab, Hamza N. Khan, Roshun Sangani, et al.
Cutaneous and Ocular Toxicology (2024) Vol. 43, Iss. 4, pp. 293-298
Closed Access | Times Cited: 1
Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events
Bennian Huo, Ling Shu, Jian-wen Xiao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database
Sammodavardhana Kaundinnyayana, Ashwin Kamath
Health Science Reports (2022) Vol. 5, Iss. 6
Open Access | Times Cited: 7
Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions
Long Meng, Jing Huang, Feng Qiu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6

Scroll to top